A clinical trial with halofantrine on patients with falciparum malaria in Colombia

Bulletin of the World Health Organization

Volumn 74, Issue 6, 1996, Pages 591-597

  Restrepo, M ^a   Botero, D ^b   Marquez, R E ^c   Boudreau, E F ^d   Navaratnam, V ^e  

^a Instituto Colombiano de Medicina Tropical   (Colombia)

^b UNIVERSIDAD PONTIFICIA BOLIVARIANA   (Colombia)

^c El Bagre   (Colombia)

^d Niro Pharma Systems   (United States)

^e SCHOOL OF PHYSICS   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

HALOFANTRINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; COLOMBIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; ELECTROCARDIOGRAM; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALE; MULTIDRUG RESISTANCE; ORAL DRUG ADMINISTRATION; PLASMODIUM FALCIPARUM; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; ANTIMALARIALS; CHILD; COLOMBIA; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HEART; HUMANS; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PHENANTHRENES; RECURRENCE;

EID: 0030484422     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Nosten F et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet, 1993, 341: 1054-1056.
2. Rinehart J et at. Evaluation of two phenanthrene-methanols for antimalarial activity in man: WR 122,455 and WR 171,669. American journal of tropical medicine and hygiene, 1976, 25: 769-774.
3. Cosgriff TM et al. Evaluation of the antimalarial activity of the phenanthrenemethanol halofantrine (WR 171,669) American journal of tropical medicine and hygiene, 1982, 31: 1075-1079.
4. Fleckenstein L et al. Pharmacokinetics and bioavailability of orally administered halofantrine (WR 171,669) in healthy volunteers. Investigational new drug report, 1983, 9847 (suppl. 10): 99-133.
5. Boudreau EF et al. Malaria: treatment efficacy of halofantrine (WR 171,669) in initial field trials in Thailand. Bulletin of the World Health Organization, 1988, 66: 227-235.
6. Restrepo A, Alvarez L, Restrepo M. [In-vivo study of P. falciparum resistance to chloroquine in Colombia. Description of resistance III.] Acta médica Colombiana, 1980, 5: 367-379.
7. Blair-Trujillo S. [Drug resistance of P. falciparum in Colombia: 1961-1986.] Biomédica, 1986, 6: 95-100.
8. Bouchaud LK et al. Clinical efficacy and pharmacokinetics of micronized halofantrine for the treatment of acute uncomplicated falciparum malaria in nonimmune patients. American journal of tropical medicine and hygiene, 1994, 51: 204-213.
9. Bazett HC. An analysis of the time relatons of electro-cardiograms. Heart, 1920, 7: 353.
10. Ambroise-Thomas P et al. Halofantrine in the treatment of P. falciparum malaria in Mali (152 cases). Proceedings of the Ninth International Congress of Infectious and Parasitic Diseases, Munich. 20-26 July 1986. Abstract 1286.
11. Coulaud JP et al. Treatment of imported cases of falciparum malaria in France with halofantnne. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1986, 80: 615-617.
12. Richard-Lenoble D et al. Efficacy, safety and acceptability of halofantrine in the treatment of acute Plasmodium falciparum malaria in African children (Gabon). Parasitology today, 1989, 5 (suppl.): 59-63.
13. Nothdurft HD et al. Halofantrine: a new substance for treatment of multidrug-resistant malaria. Clinical investigation, 1993, 71: 69-73.
14. Brasseur P et al. Fast emergence of Plasmodium falciparum resistance to halofantrine. Lancet, 1993, 341: 901-902.
15. Shanks GD et al. Halofantrine for the treatment of mefloquine chemoprophylaxis failures in Plasmodium falciparum infections. American journal of tropical medicine and hygiene, 1991, 45: 488-491.
16. Shanks GD et al. Halofantrine given with food for falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1992, 86: 233-234.
17. Ter Kuile FO et al. Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet, 1993, 341: 1044-1049.